Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why

Zoetis (ZTS) shares closed down 1.29% at $149.79, underperforming the S&P 500 and its Medical sector over the past trading session and month. Ahead of its forthcoming earnings report, consensus estimates project a 3.8% year-over-year EPS increase to $1.64 and 1.56% revenue growth to $2.43 billion, with full-year forecasts also showing modest growth. Despite a recent slight upward revision in EPS estimates, the stock trades at a significant premium with a Forward P/E of 23.94 and a PEG ratio of 2.44, both well above industry averages, leading to a Zacks Rank of #3 (Hold).

Analysis

Zoetis (ZTS) exhibited notable underperformance in the recent trading session, closing down 1.29% at $149.79 while the broader market, including the S&P 500, posted gains. This trend of lagging performance extends over the past month, with ZTS shares gaining 1.83% against a 6.54% rise in the Medical sector. The market's focus is now on the company's upcoming earnings, where consensus estimates project modest growth: a 3.8% year-over-year increase in EPS to $1.64 and a 1.56% rise in revenue to $2.43 billion. While full-year estimates also point to growth, with EPS projected to rise 7.09% and revenue 2.79%, the key concern is the stock's valuation. ZTS trades at a significant premium, with a Forward P/E ratio of 23.94, well above the industry average of 15.52. Furthermore, its PEG ratio of 2.44, compared to the industry's 1.55, suggests the stock's price may be high relative to its expected earnings growth rate. Despite a minor 0.08% upward revision in consensus EPS estimates over the last month, the combination of rich valuation and modest growth prospects underpins its current Zacks Rank of #3 (Hold).

Key Decisions for Investors

• Investors should scrutinize the upcoming earnings report to see if Zoetis can deliver results that justify its premium valuation, specifically its Forward P/E of 23.94 and PEG of 2.44, which are both significantly above industry averages.
• Given the stock's recent underperformance relative to its sector and the broader market, a cautious stance is warranted until there is a clear catalyst, such as an earnings beat or improved forward guidance, to reverse the trend.
• The current Zacks #3 (Hold) rating, reflecting a balance between stable growth forecasts and a high valuation, suggests that existing investors may consider holding their positions while prospective investors might wait for a more favorable entry point or evidence of accelerating growth.